Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | BCHE | P06276 | 7/20 | 0.66 |
| ▸ | ACHE | P22303 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloracyzine SCHEMBL30719025 | 1.00 | ALDH1A1 (0.77) | ALDH1A1KDM4EBCHEACHEMEN1 | |
| Chloracyzine SCHEMBL29388455 | 1.00 | ALDH1A1 (0.77) | ALDH1A1KDM4EBCHEACHEMEN1 | |
| Chloracyzine SCHEMBL11614590 | 0.99 | ALDH1A1 (0.79) | ALDH1A1KDM4EBCHEACHEMEN1 | |
| Chloracyzine SCHEMBL1650585 | 0.98 | ALDH1A1 (0.74) | ALDH1A1KDM4EBCHEACHEMEN1 | |
| SCHEMBL6313879 | 0.89 | BCHE (0.65) | ALDH1A1KDM4EBCHEACHECHRM2 | |
| Hydrochloric Acid SCHEMBL5499595 | 0.88 | BCHE (0.66) | ALDH1A1KDM4EBCHEACHELMNA | |
| Fluacizine SCHEMBL29388364 | 0.83 | MEN1 (0.61) | ALDH1A1KDM4EBCHEACHEMEN1 | |
| Fluacizine SCHEMBL49497 | 0.83 | MEN1 (0.61) | ALDH1A1KDM4EBCHEACHEMEN1 | |
| SCHEMBL11171388 | 0.83 | BCHE (0.75) | ALDH1A1KDM4EBCHEACHEMEN1 | |
| Fluacizine SCHEMBL1650048 | 0.81 | MEN1 (0.59) | ALDH1A1KDM4EBCHEACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 666 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-03-23 | — | — | US | claimed |
| US-11324748-B2 | Vasodilators for treatment of heart failure | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-05-10 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-9511139-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| EP-3072526-A1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | Oncomed Pharmaceuticals, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| EP-2488204-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2016-04-06 | — | — | EP | claimed |
| US-20150118232-A1 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent | ONCOMED PHARMACEUTICALS, INC. | 2015-04-30 | — | — | US | claimed |
| EP-2488204-A1 | THERAPEUTIC COMBINATION AND METHODS OF TREATMENT WITH A DLL4 ANTAGONIST AND AN ANTI-HYPERTENSIVE AGENT | Oncomed Pharmaceuticals, Inc. (US) | 2012-08-22 | — | — | EP | claimed |
| WO-2006086544-A2 | THERAPEUTIC COMBINATION OF A VEGF ANTAGONIST (VEGF TRAP) AND AN ANTI-HYPERTENSIVE AGENT | REGENERON PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| EP-1507813-A4 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LAB LTD (IN) | 2005-11-23 | — | — | EP | claimed |
| EP-1507813-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | Ranbaxy Laboratories Limited (IN) | 2005-02-23 | — | — | EP | claimed |
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2003097714-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-27 | — | — | WO | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | VASP, TNNI3, EDNRB | ALDH1A1 1929/4885KDM4E 4093/4885BCHE 1910/4885 |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | ALDH1A1 515/4885KDM4E 4011/4885BCHE 1658/4885 |
| US-11324748-B2 | Vasodilators for treatment of heart failure | VASP, TNNI3, EDNRB | ALDH1A1 1929/4885KDM4E 4093/4885BCHE 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.